QVQ Research main activities are directed to the tailor made development of VHH on inquiry. The services that are offered include design and implementation of an immunization protocol in llama; measuring immune response in the sera of the immunized animals; cloning of VHH repertoire in a phage-display plasmid; design and implement a selection strategy; delivery of a number of different VHH (sequence and >0.5 mg protein) suitable for follow up assays.
QVQ D&S main activities will be the production of larger quantities of VHH for specific goals, including crystallization studies, in vivo experiments, and VHH produced under GMP conditions for clinical imaging in human.
Two great bi-heads!
QVQ was founded in 2010 by Theo Verrips, Pim Epping, Mohamed El Khattabi, Edward Dolk, and Eefjan Breukink with the aim to develop existing VHH from the Utrecht University and newly obtained proprietary VHH into high quality imaging agents for the early detection of diseases. QVQ has broadened its own portfolio of imaging agents and further developed methodologies for directional functionalization of the VHH for imaging. In collaboration with partners in Dutch medical centres, industrial partners and institutes QVQ is the only company that can develop VHH from the immunization of llamas, library construction, selection, screening and production up to GMP scale for translation to the clinic.